Report Detail

Pharma & Healthcare Global RNAi Drugs Market Growth 2022-2028

  • RnM4495644
  • |
  • 25 November, 2022
  • |
  • Global
  • |
  • 93 Pages
  • |
  • LPI(LP Information)
  • |
  • Pharma & Healthcare

It refers to the highly conservative, double stranded RNA induced, highly specific degradation of homologous mRNA in the evolutionary process
The global market for RNAi Drugs is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

The APAC RNAi Drugs market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The United States RNAi Drugs market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The Europe RNAi Drugs market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The China RNAi Drugs market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

Global key RNAi Drugs players cover Alnylam, Novo Nordisk, Eli Lilly, Alexion and Novartis and etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.

Report Coverage
This latest report provides a deep insight into the global RNAi Drugs market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.

This report aims to provide a comprehensive picture of the global RNAi Drugs market, with both quantitative and qualitative data, to help readers understand how the RNAi Drugs market scenario changed across the globe during the pandemic and Russia-Ukraine War.

The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in K Units.

Market Segmentation:
The study segments the RNAi Drugs market and forecasts the market size by Type (siRNA, miRNA and saRNA), by Application (Hospital, Clinic and Other,), and region (APAC, Americas, Europe, and Middle East & Africa).

Segmentation by type
siRNA
miRNA
saRNA
Other

Segmentation by application
Hospital
Clinic
Other

Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Major companies covered
Alnylam
Novo Nordisk
Eli Lilly
Alexion
Novartis
Roche

Chapter Introduction
Chapter 1: Scope of RNAi Drugs, Research Methodology, etc.
Chapter 2: Executive Summary, global RNAi Drugs market size (sales and revenue) and CAGR, RNAi Drugs market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: RNAi Drugs sales, revenue, average price, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global RNAi Drugs sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global RNAi Drugs market size forecast by region, by country, by type, and application.
Chapter 13: Comprehensive company profiles of the leading players, including Alnylam, Novo Nordisk, Eli Lilly, Alexion, Novartis and Roche, etc.
Chapter 14: Research Findings and Conclusion


1 Scope of the Report

  • 1.1 Market Introduction
  • 1.2 Years Considered
  • 1.3 Research Objectives
  • 1.4 Market Research Methodology
  • 1.5 Research Process and Data Source
  • 1.6 Economic Indicators
  • 1.7 Currency Considered

2 Executive Summary

  • 2.1 World Market Overview
    • 2.1.1 Global RNAi Drugs Annual Sales 2017-2028
    • 2.1.2 World Current & Future Analysis for RNAi Drugs by Geographic Region, 2017, 2022 & 2028
    • 2.1.3 World Current & Future Analysis for RNAi Drugs by Country/Region, 2017, 2022 & 2028
  • 2.2 RNAi Drugs Segment by Type
    • 2.2.1 siRNA
    • 2.2.2 miRNA
    • 2.2.3 saRNA
    • 2.2.4 Other
  • 2.3 RNAi Drugs Sales by Type
    • 2.3.1 Global RNAi Drugs Sales Market Share by Type (2017-2022)
    • 2.3.2 Global RNAi Drugs Revenue and Market Share by Type (2017-2022)
    • 2.3.3 Global RNAi Drugs Sale Price by Type (2017-2022)
  • 2.4 RNAi Drugs Segment by Application
    • 2.4.1 Hospital
    • 2.4.2 Clinic
    • 2.4.3 Other
  • 2.5 RNAi Drugs Sales by Application
    • 2.5.1 Global RNAi Drugs Sale Market Share by Application (2017-2022)
    • 2.5.2 Global RNAi Drugs Revenue and Market Share by Application (2017-2022)
    • 2.5.3 Global RNAi Drugs Sale Price by Application (2017-2022)

3 Global RNAi Drugs by Company

  • 3.1 Global RNAi Drugs Breakdown Data by Company
    • 3.1.1 Global RNAi Drugs Annual Sales by Company (2020-2022)
    • 3.1.2 Global RNAi Drugs Sales Market Share by Company (2020-2022)
  • 3.2 Global RNAi Drugs Annual Revenue by Company (2020-2022)
    • 3.2.1 Global RNAi Drugs Revenue by Company (2020-2022)
    • 3.2.2 Global RNAi Drugs Revenue Market Share by Company (2020-2022)
  • 3.3 Global RNAi Drugs Sale Price by Company
  • 3.4 Key Manufacturers RNAi Drugs Producing Area Distribution, Sales Area, Product Type
    • 3.4.1 Key Manufacturers RNAi Drugs Product Location Distribution
    • 3.4.2 Players RNAi Drugs Products Offered
  • 3.5 Market Concentration Rate Analysis
    • 3.5.1 Competition Landscape Analysis
    • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
  • 3.6 New Products and Potential Entrants
  • 3.7 Mergers & Acquisitions, Expansion

4 World Historic Review for RNAi Drugs by Geographic Region

  • 4.1 World Historic RNAi Drugs Market Size by Geographic Region (2017-2022)
    • 4.1.1 Global RNAi Drugs Annual Sales by Geographic Region (2017-2022)
    • 4.1.2 Global RNAi Drugs Annual Revenue by Geographic Region
  • 4.2 World Historic RNAi Drugs Market Size by Country/Region (2017-2022)
    • 4.2.1 Global RNAi Drugs Annual Sales by Country/Region (2017-2022)
    • 4.2.2 Global RNAi Drugs Annual Revenue by Country/Region
  • 4.3 Americas RNAi Drugs Sales Growth
  • 4.4 APAC RNAi Drugs Sales Growth
  • 4.5 Europe RNAi Drugs Sales Growth
  • 4.6 Middle East & Africa RNAi Drugs Sales Growth

5 Americas

  • 5.1 Americas RNAi Drugs Sales by Country
    • 5.1.1 Americas RNAi Drugs Sales by Country (2017-2022)
    • 5.1.2 Americas RNAi Drugs Revenue by Country (2017-2022)
  • 5.2 Americas RNAi Drugs Sales by Type
  • 5.3 Americas RNAi Drugs Sales by Application
  • 5.4 United States
  • 5.5 Canada
  • 5.6 Mexico
  • 5.7 Brazil

6 APAC

  • 6.1 APAC RNAi Drugs Sales by Region
    • 6.1.1 APAC RNAi Drugs Sales by Region (2017-2022)
    • 6.1.2 APAC RNAi Drugs Revenue by Region (2017-2022)
  • 6.2 APAC RNAi Drugs Sales by Type
  • 6.3 APAC RNAi Drugs Sales by Application
  • 6.4 China
  • 6.5 Japan
  • 6.6 South Korea
  • 6.7 Southeast Asia
  • 6.8 India
  • 6.9 Australia
  • 6.10 China Taiwan

7 Europe

  • 7.1 Europe RNAi Drugs by Country
    • 7.1.1 Europe RNAi Drugs Sales by Country (2017-2022)
    • 7.1.2 Europe RNAi Drugs Revenue by Country (2017-2022)
  • 7.2 Europe RNAi Drugs Sales by Type
  • 7.3 Europe RNAi Drugs Sales by Application
  • 7.4 Germany
  • 7.5 France
  • 7.6 UK
  • 7.7 Italy
  • 7.8 Russia

8 Middle East & Africa

  • 8.1 Middle East & Africa RNAi Drugs by Country
    • 8.1.1 Middle East & Africa RNAi Drugs Sales by Country (2017-2022)
    • 8.1.2 Middle East & Africa RNAi Drugs Revenue by Country (2017-2022)
  • 8.2 Middle East & Africa RNAi Drugs Sales by Type
  • 8.3 Middle East & Africa RNAi Drugs Sales by Application
  • 8.4 Egypt
  • 8.5 South Africa
  • 8.6 Israel
  • 8.7 Turkey
  • 8.8 GCC Countries

9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities
  • 9.2 Market Challenges & Risks
  • 9.3 Industry Trends

10 Manufacturing Cost Structure Analysis

  • 10.1 Raw Material and Suppliers
  • 10.2 Manufacturing Cost Structure Analysis of RNAi Drugs
  • 10.3 Manufacturing Process Analysis of RNAi Drugs
  • 10.4 Industry Chain Structure of RNAi Drugs

11 Marketing, Distributors and Customer

  • 11.1 Sales Channel
    • 11.1.1 Direct Channels
    • 11.1.2 Indirect Channels
  • 11.2 RNAi Drugs Distributors
  • 11.3 RNAi Drugs Customer

12 World Forecast Review for RNAi Drugs by Geographic Region

  • 12.1 Global RNAi Drugs Market Size Forecast by Region
    • 12.1.1 Global RNAi Drugs Forecast by Region (2023-2028)
    • 12.1.2 Global RNAi Drugs Annual Revenue Forecast by Region (2023-2028)
  • 12.2 Americas Forecast by Country
  • 12.3 APAC Forecast by Region
  • 12.4 Europe Forecast by Country
  • 12.5 Middle East & Africa Forecast by Country
  • 12.6 Global RNAi Drugs Forecast by Type
  • 12.7 Global RNAi Drugs Forecast by Application

13 Key Players Analysis

  • 13.1 Alnylam
    • 13.1.1 Alnylam Company Information
    • 13.1.2 Alnylam RNAi Drugs Product Offered
    • 13.1.3 Alnylam RNAi Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.1.4 Alnylam Main Business Overview
    • 13.1.5 Alnylam Latest Developments
  • 13.2 Novo Nordisk
    • 13.2.1 Novo Nordisk Company Information
    • 13.2.2 Novo Nordisk RNAi Drugs Product Offered
    • 13.2.3 Novo Nordisk RNAi Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.2.4 Novo Nordisk Main Business Overview
    • 13.2.5 Novo Nordisk Latest Developments
  • 13.3 Eli Lilly
    • 13.3.1 Eli Lilly Company Information
    • 13.3.2 Eli Lilly RNAi Drugs Product Offered
    • 13.3.3 Eli Lilly RNAi Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.3.4 Eli Lilly Main Business Overview
    • 13.3.5 Eli Lilly Latest Developments
  • 13.4 Alexion
    • 13.4.1 Alexion Company Information
    • 13.4.2 Alexion RNAi Drugs Product Offered
    • 13.4.3 Alexion RNAi Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.4.4 Alexion Main Business Overview
    • 13.4.5 Alexion Latest Developments
  • 13.5 Novartis
    • 13.5.1 Novartis Company Information
    • 13.5.2 Novartis RNAi Drugs Product Offered
    • 13.5.3 Novartis RNAi Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.5.4 Novartis Main Business Overview
    • 13.5.5 Novartis Latest Developments
  • 13.6 Roche
    • 13.6.1 Roche Company Information
    • 13.6.2 Roche RNAi Drugs Product Offered
    • 13.6.3 Roche RNAi Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.6.4 Roche Main Business Overview
    • 13.6.5 Roche Latest Developments

14 Research Findings and Conclusion

Summary:
Get latest Market Research Reports on Pharma & Healthcare. Industry analysis & Market Report on Pharma & Healthcare is a syndicated market report, published as Global RNAi Drugs Market Growth 2022-2028. It is complete Research Study and Industry Analysis of Pharma & Healthcare market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

Last updated on

REPORT YOU MIGHT BE INTERESTED

Purchase this Report

$3,660.00
$7,320.00
3,030.48
6,060.96
3,517.26
7,034.52
509,618.40
1,019,236.80
299,022.00
598,044.00
Credit card Logo

Related Reports


Reason to Buy

Request for Sample of this report